Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors - Wikidata - awgldk - TriplyDB

Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors

Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors

http://www.wikidata.org/entity/Q33702325

about

The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer Increased μ-opioid receptor expression in metastatic lung cancer The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation Morphine use in cancer surgery Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer.MOR1 expression in gastric cancer: a biomarker associated with poor outcome.Management of opioid-induced constipation in cancer patients: focus on methylnaltrexone.Methylnaltrexone for the treatment of opioid-induced constipation.The mu opioid receptor: A new target for cancer therapy?Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer.Could Perioperative Opioid Use Increase the Risk of Cancer Progression and Metastases?Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy.Opium Use and Risk of Pancreatic Cancer: A Prospective Cohort Study.

P2860

Q28541351-D8F43284-8E71-4D0B-98FA-735C2BAC03F9 Q33951500-325D09FE-334F-4DE5-86D5-F49C803B8FED Q35083162-56CF60E2-05DA-4578-BBA6-6DBDD5D12645 Q35151843-12329F53-E222-4F25-9274-9B55FB840498 Q37051227-497A0291-D8EA-4D8F-9D25-118938C88AA9 Q37700635-E3CDDD31-0EFA-4941-80D8-B506456248CC Q37993108-611A6BD8-1905-493E-9D30-42D3021CF609 Q38069607-776B8D18-4ABA-4277-BD3A-1AD4FC78EF18 Q38515846-6B4A928C-1B5B-4865-B58C-1B2CFA70D9A0 Q39442254-DA828F7A-C112-42D8-87D6-81706AE41B35 Q41644051-293753B7-E20F-4855-A690-349364CB59F3 Q47099537-02698B74-D413-467C-BF49-0FE7EDDA25F4 Q47273706-092109FD-0A6E-428F-99FA-0A8219085F3F

P2860

Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors

http://www.wikidata.org/entity/Q33702325

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors

@ast

Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors

@en

type

label

Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors

@ast

Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors

@en

prefLabel

Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors

@ast

Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors

@en

P1433

Q33702325-FB9AC7A8-BC14-4C13-BB4B-294B53141868

P1476

Q33702325-C44F0A0E-F98E-4742-8927-D4A62C855CDC

P2093

Q33702325-0C2D2A67-FFF2-4BC9-A1F5-17B320C35672

Q33702325-36D24B4A-8EB8-4821-94BA-0B6967A19B41

Q33702325-4A51CD04-ED0B-465E-BFBE-3092B47BED78

Q33702325-8C42A493-4D7D-4E66-B145-1BD402EF340F

Q33702325-8E2BFDAC-9025-40C4-B8FF-E4F84146521C

Q33702325-9E159566-BF2E-42EE-BD91-5AE344DD2FC3

Q33702325-D2D6A471-DB38-4297-ACB1-4A9821B04977

Q33702325-ED289712-A125-4BBE-BD52-2132EC2E145E

P2860

Q33702325-03B4C27E-DAE2-45C3-B8BF-659C53B7A315

Q33702325-08C4BAA6-BE1E-48AD-9F33-233B1EC5F0A6

Q33702325-108C2074-4EA5-4828-99A4-54FB7E4D01C4

Q33702325-13F0D4C9-370A-4030-9045-340F89E477B5

Q33702325-19129C22-A996-4497-977D-1ED48D63C17A

Q33702325-275C6AF5-D4A6-4214-A9F9-B30F182DE956

Q33702325-2FF037E6-633A-4BB7-AF68-EABAE36F6D6F

Q33702325-365BD387-210D-4C76-A288-448DA7015763

Q33702325-435AC13A-E1FE-486C-ACC1-4F0751EEB590

Q33702325-4C140C3D-ED55-4740-AEA3-6C2BA4A54BB9

P2888

Q33702325-125DFC4C-A683-4373-BCFA-3F9B79170877

P304

Q33702325-62E100D7-1ADB-45E0-9806-3176C0EBA845

P31

Q33702325-95755CE2-31F8-4227-9498-9FCD7D0317CC

P356

Q33702325-C0094566-109D-427A-AB43-856FF7191220

P433

Q33702325-B0EE5C6A-C2D4-42C4-94B2-08053AEB6512

P478

Q33702325-22251351-F070-43FD-A894-4F56E51C1967

P50

Q33702325-A1B72D97-E939-4309-8DC4-09B08061B901

P577

Q33702325-641E47CB-C69A-4A9B-8B79-55E6EABDDBCF

P5875

Q33702325-7B80F8D1-D4EA-4A50-AFB6-FF9F2FE5D353

P6179

Q33702325-7B08766F-897A-4EA0-9E33-98521A611321

P698

Q33702325-14835302-5122-4364-BB9B-9DDC8295DA6D

P932

Q33702325-6FCE52D4-3B85-4F2F-853F-EC859805CE6A

P356

P1433

Journal of angiogenesis research

P1476

Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors

@en

P2093

Biji Mathew

http://www.w3.org/2001/XMLSchema#string

Frances E Lennon

http://www.w3.org/2001/XMLSchema#string

Jessica H Siegler

http://www.w3.org/2001/XMLSchema#string

Joe Gn Garcia

http://www.w3.org/2001/XMLSchema#string

Jonathan Moss

http://www.w3.org/2001/XMLSchema#string

Liliana Moreno-Vinasco

http://www.w3.org/2001/XMLSchema#string

Nurbek Mambetsariev

http://www.w3.org/2001/XMLSchema#string

Patrick A Singleton

http://www.w3.org/2001/XMLSchema#string

P2860

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

Synergistic effects of methylnaltrexone with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor-induced angiogenesis

AKT/PKB signaling: navigating downstream

Regulation of Akt/PKB activation by tyrosine phosphorylation

Current development of mTOR inhibitors as anticancer agents

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

Methylnaltrexone for opioid-induced constipation in advanced illness.

Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients.

Drug synergism: its detection and applications.

P2888

P304

5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/2040-2384-2-5

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-02-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42344116

http://www.w3.org/2001/XMLSchema#string

P6179

1040681695

http://www.w3.org/2001/XMLSchema#string

P698

20298531

http://www.w3.org/2001/XMLSchema#string

P932

2831839

http://www.w3.org/2001/XMLSchema#string